Sun Pharma falls short of bond fundraising target amid rising yields
Sun Pharmaceutical secured new business.
· Economic Times Markets
Sun Pharma successfully secured ₹7,816 crore in its latest fundraising round, yet it fell short of its ambitious ₹10,000-crore target. The company opted for five- and seven-year bonds, pricing them at 8.05% and 8.20% respectively.
The analysis
Sun Pharmaceutical reported ₹7,816 crore, ₹10,000 and ₹2,100 crore, with movement of 8.05% and 8.20% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.7% on the day at ₹1,758.00, and has returned -9.5% over three months. It sits 12% below its 52-week high. The pharma & healthcare sector has moved -4.9% over the same period, so Sun Pharmaceutical is running 4.6 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- The company directly in focus is SUNPHARMA.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads negative.